Comparison of Hypermetabolic and Hypoxic Volumes Delineated on [18F]FDG and [18F]Fluoromisonidazole PET/CT in Non-small-cell Lung Cancer Patients

Thureau, S.; Modzelewski, Romain; Bohn, Pierre; Hapdey, Sébastien; Gouel, Pierrick; Dubray, Bernard; Véra, Pierre

doi:10.1007/s11307-019-01422-6

Cited by 6 publications

(2 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Other parameters such as tumour-to-blood ratios might be promising in hypoxic region determination [ 168 ]. Different kinetics and uptake profiles were obtained in a comparison of 34 non-resectable NSCLC hypermetabolic and hypoxic volumes, investigated by [ 18 F]-FDG and [ 18 F]-MISO [ 174 ]. To date, [ 18 F]-FDG PET based on SUV is used in daily clinical practice to determine malignancy probability before histologic confirmation or to perform a whole-body staging.…”

Section: Available Tools To Detect Hypoxia In Clinical Practicementioning

confidence: 99%

Hypoxia in Lung Cancer Management: A Translational Approach

Ancel

Perotin

Dewolf

et al. 2021

Cancers

View full text Add to dashboard Cite

Lung cancer represents the first cause of death by cancer worldwide and remains a challenging public health issue. Hypoxia, as a relevant biomarker, has raised high expectations for clinical practice. Here, we review clinical and pathological features related to hypoxic lung tumours. Secondly, we expound on the main current techniques to evaluate hypoxic status in NSCLC focusing on positive emission tomography. We present existing alternative experimental approaches such as the examination of circulating markers and highlight the interest in non-invasive markers. Finally, we evaluate the relevance of investigating hypoxia in lung cancer management as a companion biomarker at various lung cancer stages. Hypoxia could support the identification of patients with higher risks of NSCLC. Moreover, the presence of hypoxia in treated tumours could help clinicians predict a worse prognosis for patients with resected NSCLC and may help identify patients who would benefit potentially from adjuvant therapies. Globally, the large quantity of translational data incites experimental and clinical studies to implement the characterisation of hypoxia in clinical NSCLC management.

show abstract

Section: Available Tools To Detect Hypoxia In Clinical Practicementioning

confidence: 99%

Hypoxia in Lung Cancer Management: A Translational Approach

Ancel

Perotin

Dewolf

et al. 2021

Cancers

View full text Add to dashboard Cite

show abstract

“…This approach is named dose painting or biologically-guided dose painting. [ 18 F]FMISO appeared to have a different distribution without any correlation with [ 18 F]FDG and might conduce to different approaches of targeting hypoxia tumor regions [ 59 , 60 ].…”

Section: Therapeutic Approaches To Overcome Radioresistance In Nsclcmentioning

confidence: 99%

Radioresistance of Non-Small Cell Lung Cancers and Therapeutic Perspectives

Césaire

Montanari

Curcio

et al. 2022

Cancers

View full text Add to dashboard Cite

Survival in unresectable locally advanced stage non-small cell lung cancer (NSCLC) patients remains poor despite chemoradiotherapy. Recently, adjuvant immunotherapy improved survival for these patients but we are still far from curing most of the patients with only a 57% survival remaining at 3 years. This poor survival is due to the resistance to chemoradiotherapy, local relapses, and distant relapses. Several biological mechanisms have been found to be involved in the chemoradioresistance such as cancer stem cells, cancer mutation status, or the immune system. New drugs to overcome this radioresistance in NSCLCs have been investigated such as radiosensitizer treatments or immunotherapies. Different modalities of radiotherapy have also been investigated to improve efficacity such as dose escalation or proton irradiations. In this review, we focused on biological mechanisms such as the cancer stem cells, the cancer mutations, the antitumor immune response in the first part, then we explored some strategies to overcome this radioresistance in stage III NSCLCs with new drugs or radiotherapy modalities.

show abstract